News Release

Asieris achieved objectives in the grant of Supporting Science and Technology

In March 2012, Asieris Pharmaceuticals Company received the grant from the Science and Technology Department of Jiangsu Province for APL-1202 to be designated as a Supporting Science and Technology -Social Development Project. One of the objectives was the acceptance by the China Drug and Food Administration of APL-1202’s Clinical Trial Application for treating non-muscle invasive bladder cancer before March 2014. The development of APL-1202 project was so successful that the stated objectives were exceeded and ahead of schedule. Asieris submitted the Clinical Trial Application in September 2012, 18 months ahead of the deadline, and received the approval in August 2013. Jiangsu Science and Technology Department organized a grant conclusion review meeting on November 29, 2013. The attending reviewers included professors from the Academy of Military Medical Sciences and China Pharmaceutical University, and experts from well-known global pharmaceutical companies. Officials from the Bureau of Science and Technology in China Medical City (Taizhou) Medical High-Tech Park also attended the meeting. The reviewers unanimously concluded that the grant’s objectives were completely achieved and in some areas exceeded.

(Photos from the project acceptance review meeting)